GLP-1 prescription medications Ozempic®, Wegovy®, Rybelsus®, Trulicity®, Mounjaro®, and Zepbound™ are used to treat type 2 diabetes and obesity. Plaintiffs allege Nonarteritic Anterior Ischemic Optic Neuropathy vision loss as a result of taking these medications. On October 16, 2025, the Supreme Court designated pending and future New Jersey state court litigation alleging gastrointestinal injuries from use of GLP-1 prescription medications as multicounty litigation and assigned it for centralized management to Bergen County.